Efficacy and safety results of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

被引：0
|
作者：
Menter, A. [1 ]
Gottlieb, A. [2 ]
Leonardi, C. [3 ]
Kerdel, F. [4 ]
Gu, Y. [5 ]
Valdes, J. [5 ]
机构：
[1] Baylor Res Inst, Dallas, TX USA
[2] Tufts Med Ctr, Boston, MA USA
[3] Cent Dermatol, St Louis, MO USA
[4] Florida Acad Dermatol Ctr, Miami, FL USA
[5] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2011年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [21] The population pharmacokinetics of briakinumab in subjects with moderate to severe plaque psoriasis
    Hruska, M.
    Paulson, S.
    Kaul, M.
    Awni, W.
    Noertersheuser, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S93 - S93
  • [22] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
    Lebwohl, Mark G.
    Kircik, Leon
    Duffin, Kristina Callis
    Pariser, David
    Hooper, Michele
    Wenkert, Deborah
    Thompson, Elizabeth H. Z.
    Yang, Jun
    Kricorian, Greg
    Koo, John
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) : 385 - 392
  • [23] Efficacy and safety of etanercept in moderate to severe plaque psoriasis using two different dosing regimens
    Mazzotta, A
    Costanzo, A
    Giunta, A
    Chimenti, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB201 - AB201
  • [24] Characterization of etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients with moderate to severe plaque psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Gary
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB67 - AB67
  • [25] Safety and efficacy study on etanercept in patients with plaque psoriasis
    Costanzo, A
    Mazzotta, A
    Papoutsaki, M
    Chimenti, S
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (01) : 187 - 189
  • [26] Efficacy and safety of secukinumab in moderate to severe plaque psoriasis
    Aparicio Rubio, Celia
    Monteagudo Santolaya, Emilio
    Cornejo Uixeda, Silvia
    Prieto Castello, Manuel
    Antonino de la Camara, Gonzalo
    Quintana Vergara, Belen
    Sanchez Alcaraz, Agustin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 299 - 299
  • [27] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [28] A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
    de Vries, A. C. Q.
    Thio, H. B.
    de Kort, W. J. A.
    Opmeer, B. C.
    van der Stok, H. M.
    de Jong, E. M. G. J.
    Horvath, B.
    Busschbach, J. J. V.
    Nijsten, T. E. C.
    Spuls, Ph. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 624 - 633
  • [29] Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
    Reich, Kristian
    Soung, Jennifer
    Gooderham, Melinda
    Zhang, Zuoshun
    Nograles, Kristine
    Day, Robert M.
    Ferris, Laura
    Goodfield, Mark
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [30] Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
    Mostafa, N. M.
    Nader, A. M.
    Noertersheuser, P.
    Okun, M.
    Awni, W. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 490 - 497
12345